Breaking News, Collaborations & Alliances

Aptar Pharma Twister Chosen for Asthma Therapy

Partners with Shanghai Sine Promod Pharmaceutical to launch its new Budesonide DPI in China

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aptar Pharma, a provider of aerosol, injection and spray delivery systems for biotech, healthcare and pharma products has partnered with Shanghai Sine Promod Pharmaceutical Co., Ltd. to develop and launch its new Budesonide DPI (dry powder inhaler), which uses Aptar Pharma’s Twister Dry Powder Inhaler. Budesonide DPI is designed for maintenance therapy in the treatment of asthma and is one of the first drug products manufactured locally and marketed in China. The company says this cost-effect...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters